{"entity":{"id":"nct07371208","kind":"trial","name":"Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer","aka":["ST-A-TN"],"tldr":"A phase 2 trial of sacituzumab tirumotecan in triple-negative breast cancer, run by Shanghai Jiao Tong University School of Medicine, now recruiting.","summary":"Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT07371208 by Shanghai Jiao Tong University School of Medicine, with a registry enrolment figure of 40 participants, started 2025-12-24 and due to reach its primary completion in 2028-08. Interventions recorded: SKB264. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: \"* Diagnosis: Histologically and/or cytologically confirmed primary triple-negative breast cancer (TNBC) (excluding inflammatory breast cancer), meeting the criteria of tumor size ≥2 cm, clinical lymph node stage cN0 to cN3, and M0 (no distant metastasis)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07371208","url":"https://clinicaltrials.gov/study/NCT07371208"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["sacituzumab-tirumotecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07371208","phase":"2","setting":"Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer","sponsor":"Shanghai Jiao Tong University School of Medicine","participation":[{"nct":"NCT07371208","source":"https://clinicaltrials.gov/study/NCT07371208","fetchedAt":"2026-10-07T16:55:42.201Z","studySha256":"41fe34e2ed746c717c9ecc2d0b364246820e6fb8c09af02d5084f1d584582f46","overallStatus":"RECRUITING","lastUpdatePosted":"2026-01-27","leadSponsor":"Shanghai Jiao Tong University School of Medicine","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"65 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":40,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-12-24","startedType":"actual","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07371208/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}